Inhalation Sciences receives new order worth 41,000 Euro from returning big pharma customer

This repeat business strengthens ISAB's long-term relationship with the customer and further confirms the trust in the company's technology and expertise within inhalation research.

"The fact that a global player once again chooses to invest in our technology is a strong validation of the quality and precision our systems deliver. We see this as a confirmation of our long-term collaboration and the strategic importance of our products in inhalation research. The order reinforces ISAB's position as a leading provider of preclinical inhalation research technology and confirms the growing demand for our solutions", says Manoush Masarrat, CEO of Inhalation Sciences.

For more information, please contact:

Manoush Masarrat, CEO
Mobile: +46 (0) 73 628 9153
E-mail: manoush.masarrat@inhalation.se

About Inhalation Sciences Sweden AB (publ)

Inhalation Sciences Sweden AB (publ) develops and commercializes world-leading instruments and services for research into inhalation. The company's patented lab instruments PreciseInhale® and DissolvIt® enable researchers in the pharma industry to make drug pipeline decisions at an early stage, saving time and resources for R&D departments, and enables researchers in academic institutions to define how aerosols and small particles impact our lungs, and so our health, when being inhaled.

Datum 2025-04-15, kl 08:35
Källa Cision
Bifogade filer
Vill du synas här? Kontakta hej@allaaktier.se. Vår sajt har 125 000 sidvisningar och 17 000 unika besökare per månad. Vår discord har 7800 medlemmar. Detta är aktiva sparare med ett stort aktieintresse. Behöver du nå ut till denna målgrupp så hör av dig!